Ruxolitinib

20 interactions 1 explained in plain English
Also sold as: Jakafi Opzelura
About Ruxolitinib

Ruxolitinib is used to treat myelofibrosis (a cancer of the bone marrow in which the bone marrow is replaced by scar tissue and causes decreased blood cell production). It is also used to treat polycythemia vera (PV; a slow growing cancer of the blood in which the bone marrow makes too many red blood cells) in people w… Read the full Ruxolitinib drug information page →

Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Jun 30, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Abatacept Injection Asciminib Fluorouracil Injection Octreotide Baricitinib Octreotide Injection
19 Major 1 Moderate
All (20) Major (19) Moderate (1)

Major

Ruxolitinib Abatacept Injection Orencia An increased risk of infection Details Ruxolitinib Asciminib Scemblix Increased CYP2C9/CYP3A4 substrates with NTI exposure and an increased risk of CYP2C9/CYP3A4 substrates-related side effects Details Ruxolitinib Azathioprine Azasan Therapeutic duplication Details Ruxolitinib Abatacept Orencia Explained An increased risk of infection Details Ruxolitinib Baricitinib Olumiant An increased risk of infection Details Ruxolitinib Capecitabine Xeloda Increased exposure of CYP2C9 substrates and an increased risk of CYP2C9 substrates-related adverse effects Details Ruxolitinib Cyclophosphamide Cytoxan® Therapeutic duplication Details Ruxolitinib Cyclophosphamide Injection Cytoxan® Injection Therapeutic duplication Details Ruxolitinib Enasidenib Idhifa Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Ruxolitinib Fluorouracil Adrucil Increased exposure of CYP2C9 substrates and an increased risk of CYP2C9 substrates-related adverse effects Details Ruxolitinib Fluorouracil Injection Adrucil Increased exposure of CYP2C9 substrates and an increased risk of CYP2C9 substrates-related adverse effects Details Ruxolitinib Fluorouracil Topical Carac Increased exposure of CYP2C9 substrates and an increased risk of CYP2C9 substrates-related adverse effects Details Ruxolitinib Ketoconazole Topical Extina® Foam Increased ruxolitinib exposure and an increased risk of ruxolitinib-related adverse effects Details Ruxolitinib Lanreotide Injection Somatuline Altered exposure to CYP3A4 substrate Details Ruxolitinib Lefamulin Xenleta Increased sensitive CYP3A4 substrate exposure and an increased risk of sensitive CYP3A4 substrate-related toxicities associated wi... Details Ruxolitinib Letermovir Injection Prevymis Increased CYP3A substrate exposure Details Ruxolitinib Mitapivat Aqvesme Reduced CYP3A/CYP2C9 substrate exposure Details Ruxolitinib Octreotide Bynfezia Increased exposure of CYP3A4 substrates with narrow therapeutic index Details Ruxolitinib Octreotide Injection Bynfezia Increased exposure of CYP3A4 substrates with narrow therapeutic index Details

Moderate

Ruxolitinib Levothyroxine Ermeza Increased risk of hypothyroidism Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.